2020-2027 Analysis and Review Hydroxychloroquine Sulfate Tablets Market

Hydroxychloroquine Sulfate Tablets Market

Hydroxychloroquine Sulfate Tablets Market By Indication (Malaria, Rheumatoid Arthritis, Lupus Erythematosus and Others), By End User (Hospital Pharmacy, Retail Pharmacy and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 – 2027

13-02-2020 REP-HC-5033 40 Tables 112 pages Format

The hydroxychloroquine sulfate tablets market was valued at USD445.1 Mn by 2019. Rising prevalence of malaria in the tropical and subtropical regions of the world primarily determines the demand for hydroxychloroquine sulfate tablets as a first-line drug therapy. Furthermore the drug has found therapeutic efficacy in treating autoimmune disorders such as rheumatoid arthritis and lupus erythematosus etc. Currently, the Center for Disease Control and Prevention (CDC) is investigating the drug for its ability to treat the notorious COVID-19 infection.

 Hydroxychloroquine Sulfate Tablets Market

Hydroxychloroquine sulfate is rapidly absorbed through the gastrointestinal tract and eliminated by the kidneys. It is a lipophilic weak base drug that easily passes the plasma membrane, it increases the lysosomal pH of the antigen-presenting cells. In the inflammatory condition it usually blocks the toll-like receptors signals and thereby reduces the inflammatory process in the autoimmune diseases. It is currently mentioned in the World Health Organization (WHO) list of essential medicines. Currently it is under investigation for its therapeutic efficacy in the treatment of COVID-19 infection.

The major segments related to the hydroxychloroquine sulfate tablets market are:

By Indication (2017–2027; US$ Mn)

Malaria

Rheumatoid Arthritis

Lupus Erythematosus

Others

By End User (2017–2027; US$ Mn)

Hospital Pharmacy

Retail Pharmacy

Others

Geography Segment(2017–2027; US$ Mn)

North America

United States
Canada

Europe

United Kingdom
Germany
Rest of Europe

Asia Pacific

China
Japan
Rest of Asia Pacific

Latin America (LATAM)

Brazil
Mexico
Rest of Latin America

Middle East and Africa (MEA)

GCC
Rest of MEA 

Justification for study?

  • The intention of the study is to give a comprehensive outlook of the global hydroxychloroquine sulfate tablets market
  • The overall segmentation of the hydroxychloroquine sulfate tablets market, by indication, end-user and geography is minutely studied. Malaria and hospital are dominating the indication and end-user segments respectively
  • Significant rise in the malaria infection and therapeutic efficacy of hydroxychloroquine sulfate in rheumatoid arthritis, lupus erythematosus primarily drives the market growth
  • Recent findings pertaining to the therapeutic efficacy of hydroxychloroquine sulfate tablets in the treatment of COVID-19 will further accentuate its market growth 

Report gist?

  • The study of the global hydroxychloroquine sulfate tablets market includes qualitative analysis of factors such as drivers, restraints, and opportunities
  • The report covers qualitative and quantitative analysis of the overall market segmented on the basis of indication and end-user and categorization of the same at the geography level
  • This research report presents the analysis of each segment from 2017 to 2027 in which 2019 is considered as the base year. Compounded annual growth rate is calculated for the respective segments from 2020 to 2027
  • The study includes the profiles of major market players with a significant global and regional presence along with top company positioning

Significant customers?

  • This study is suitable for industry participants and stakeholders in the pharmaceutical industry engaged in manufacturing and marketing of hydroxychloroquine sulfate tablets which is gaining huge demand owing to its therapeutic efficacy for treating malaria, rheumatoid arthritis and currently COVID-19
  • The report will benefit physicians engaged in treating infectious and musculoskeletal disorders
  • Managers with financial institutions looking to publish recent and forecasted statistics pertaining to hydroxychloroquine sulfate tablets market
  • Financial institutions venture capitalist, analysts, investors, government organizations, policymakers, regulatory authorities, researchers, looking for insights into the market to determine future strategies 

Segment Analysis

In the present scenario hydroxychloroquine is widely employed in the treatment of malaria in regions where chloroquine resistance is not reported. It is used as a first-line drug therapy for treating malarial infection in the sub-Saharan African regions. The posology associated with malaria treatment is 400mg weekly starting 2 weeks before exposure and is continued for 4 weeks after leaving the endemic area. For the treatment of rheumatoid arthritis (DMARD) the posology is 400-600 mg/day in the BID, used in combination with corticosteroids or salicylates for better results. In the treatment of lupus erythematosus it is used in combination with artemisinin as a 200mg single dose per day.

Hospital pharmacy is spearheading the end-user segment for hydroxychloroquine sulfate tablets market. The ability to dispense a different dose of hydroxychloroquine across all age groups primarily determines its market significance and positive growth. Retail pharmacies are gaining huge popularity in the developing regions owing to the presence of huge generic market in the developing regions selling hydroxychloroquine sulfate tablets at cheap price and its capability to serve the medical needs of patients in the far-flung remote areas.

Middle East and Africa are presently holding the largest market share in the geography segment for hydroxychloroquine sulfate tablets market. The chief attributing factors responsible for its market dominance is the rising prevalence of malaria in the region. As per the latest research citings presented by the World Health Organization (WHO), the estimated deaths associated with malaria in 2018 stood at 405,000 in which 94% of deaths were reported from Africa. Currently the majority of the countries of Sub-Saharan Africa receive anti-malarial medical aid from healthcare agencies such as WHO, Red Cross, etc. Latin America stands in the 2nd position on account of the presence of widespread rain forest area infested with P.ovale, P.vivax, and P. falciparum-infected mosquitos. Asia Pacific is set to register rampant market growth during the forecast period on account of the rising incidence of malarial infection owing to the tropical weather in the majority of the SE Asian countries. Hydroxychloroquine is widely used in combination therapy with artemisinin to treat lupus erythematosus in the developed regions such as North America and Europe.

Select License Type

$4,600
$6,600
$9,500

Safe and Secure SSL Encrypted

Have a Question?

We will help you find what you are looking for.

Call 1-518-730-1560

Contact sales

How can we help you?

Get in touch with us or find an office closest to you.